Evolyutsiya gormonal'noy kontratseptsii (obzor literatury)


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The article presents the literature data on the evolution of hormonal contraception, types and composition of modern hormonal preparations; modes and routes of administration are described; safety data and features of the influence of contraceptives on women's health are discussed.

全文:

受限制的访问

作者简介

O. Pustotina

Email: pustotina@gmail.com

参考

  1. Burkman R., Bell C., Serfaty D. The evolution of combined oral contraception: improving the isk to benefit ratio. Contraception. 2011; 84:19-34.
  2. Pincus G., Chang M.C., Hafez E.S., Zarrow M.X., Merrill A. Effects of certain 19-nor steroids on reproductive processes in animals. Science. 1956;124:890-95.
  3. Pincus G., Paniagua M., Pendleton A., Laraque F., Nicolas R., Borno R., Pean V. Effectiveness of an oral contraceptive. Science. 1959;130:81.
  4. Dhont M. History of oral contraception. Eur. J. Contracept Reprod Health Care. 2010;15(S2):12-8.
  5. Gerstman B.B., Piper J.M., Tomita D.K., Ferguson W.J., Stadel B.V., Lundin F.E. Oral contraceptive estrogen dose and risk of deep venous thromboembolic disease. Am. J. Epidem. 1991;133:32-7.
  6. Kronenberg H.M., Melmed S., Polonsky K.S., Larsen P.R. Williams Textbook of Endocrinology. 11th edition, Elsevier Ltd., 2008.
  7. The Oral Contraceptive and Hemostasis Study Group. The effect of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomazed multicenter study. Contraception. 2003;67: 173-85.
  8. US Selected Practice Recommendations for Contraceptive Use, 2013. http://www.cdc.gov/ mmwr/pdf/rr/rr62e0614.pdf.
  9. WHO. Medical eligibility criteria for contraceptive use. Fouth edition, 2009. 125 p.
  10. Speroff L., Fritz M.A. Clinical Gynecologic Endocrinology and Infertility, 7th ed., 2005.
  11. Clinical Effectiveness Unit. Combined hormonal contraception. London (UK): Faculty of Sexual and Reproductive Healthcare; 2011 http:// guideline.gov/content.aspx?f=rss&id=36071
  12. Grow D.R. Metabolism of endogenous and exogenous reproductive hormones. Obstet. Gynecol. Clin. North Am. 2002;29:425-36.
  13. Porter J.B., Hershel J., Walker A.M. Mortality among oral contraceptive users. Obstet. Gynecol. 1987;70:29-32.
  14. Zeun S., Lu M., Uddin A., Zeiler B., Morrison D., Blode H. Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest. Eur. J. Contracept Reprod Health Care. 2009;14:221-32.
  15. Agren U.M., Anttila M., Maenpaa-Liukko K., Rantala M.L., Rautiainen H., Sommer W.F., Mommers E. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism. Eur. J. Contracept Reprod Health Care. 2011;16:444-57.
  16. Jensen J.T. Evaluation of a new estradiol oral contraceptive: estradiol valerate and dieogest. Expert Opin. Pharmacother. 2010; 1 1:1147-57.
  17. Duijkers I.J., Klipping C., Grob P., Korver T. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17 beta-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol. Eur. J. Contracept Reprod Health Care. 2010;15:314-25.
  18. Mansour D., Verhoeven C., Sommer W., Weisberg E., Taneepanichskul S., Melis G.B., SundströmPoromaa I., Korver T. Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. Eur. J. Contracept Reprod Health Care. 2011;16:430-43.
  19. Westhoff C., Kaunitz A.M., Korver T., Sommer W., Bahamondes L., Darney P., Verhoeven C. Efficacy, safety, and tolerability of a monophasic oral contraceptive containing nomegestrol acetate and 17β-estradiol: a randomized controlled trial. Obstet. Gynecol. 2012;119:989-99.
  20. Schindler A.E., Campagnoli C., Druckmann R., Huber J., Pasqualini J.R., Schweppe K.W., Thijssen J.H. Classification and pharmacology of progestins. Maturitas. 2008;61:171-80.
  21. Stanczyk F.Z. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Rev. Endocr. Metab. Disord. 2002;3:211-24.
  22. Lello S. Nomegestrol acetate: pharmacology, safety profile and therapeutic efficacy. Drugs. 2010;70:541-59.
  23. Mueck A.O., Sitruk-Ware R. Nomegestrol acetate, a novel progestogen for oral contraception. Steroids. 2011;76(6):531-39.
  24. Christin-Maitre S., Serfaty D., Chabbert-Buffet N., Ochsenbein E., Chassard D., Thomas J.L. Comparison of a 24-day and a 21-day pill regimen for the novel combined oral contraceptive, nomegestrol acetate and 17β-estradiol (NOMAC/E2): a double-blind, randomized study. Hum Reprod.2011;26:1338-47.
  25. Read C.M. New regimens with combined oral contraceptive pills-moving away from traditional 21/7 cycles. Eur. J. Contracept Reprod Health Care. 2010;15(2):32-41.
  26. Seracchioli R., Mabrouk M., et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomised, con trolled trial. Fertil Steril. 2010;93:52-6.
  27. Klipping C., Duijker I., Fortier M.P., Marr J., Trummer D., Elliesen J. Long-term tolerability of ethinylestradiol 20mg/drospirenone 3 mg in flexible extended regimen: results from a randomized, controlled, multicenter study. J. Fam. Plann Reprod Health Care. 2012;38:84-93.
  28. Trussel J. Contraceptive Failure in the United States. Contraception. 2011;83:397-404.
  29. Trussell J., Henry N., Hassan F., Prezioso A., Law A., Filonenko A. Burden of unintended pregnancy in the United States: potential savings with increased use of long-acting reversible contraception. Contraception. 2013;87:154-61.
  30. Blumenthal P., Gemzell-Danielsson K., Marintcheva-Petrova M. Tolerability And Clinical Safety of IMPLANON®. Eur J Contrac and Reprod Health Care. 2008;13(1):29-36.
  31. Hatcher R.A., Trussel J., Nelson A.L., et al. Contraceptive Technology. 19th revised ed. New York, NY: Ardent Media, 2007.
  32. Trussell J., Wynn L.L. Reducing unintended pregnancy in the United States. Contraception. 2008;77:1-9.
  33. Winner B., Peipert J.F., Zhao Q., Buckel C., Madden T., Allsworth J.E., Secura G.M. Effectiveness of long-acting reversible contraception. N. Engl. J. Med. 2012;366:1998-2008.
  34. Lidegaard O. Hormonal contraception and venous thromboembolic risk in midlife women. Editorial. Maturitas. 2013;74:1-12.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2015
##common.cookie##